论文部分内容阅读
目的:探讨支气管肺泡灌洗液(BALF)中可溶性细胞角蛋白19片段(CYFRA21—1)检测对非小细胞肺癌(NSCLC)的诊断价值。方法:应用免疫放射法检测50例首次确诊的NSCLC患者BALF中CYFRA21—1水平,以肺良性疾病为对照组,并与血清中比较。采用ROC曲线确定BALF是CYFRA21—1的阳性值(>60μg/l),结果:NSCLC患者BALF中CYFRA21—1水平明显高于对照组(P<0.01),其阳性率为75.5％,明显高于同组血清的阳性率(53.1％)(P<0.05)。结论:BALF中CYFRA21—1检测对肺癌有较高的诊断价值。
Objective: To investigate the diagnostic value of cytokeratin 19 fragment (CYFRA21-1) in bronchoalveolar lavage fluid (BALF) for non-small cell lung cancer (NSCLC). Methods: The levels of CYFRA21-1 in BALF of 50 first diagnosed NSCLC patients were detected by immunoradiography. The lung benign disease was used as the control group and compared with the serum level. The positive value of CYFRA21-1 (> 60μg / l) was determined by ROC curve. Results: The CYFRA21-1 level in BALF of NSCLC patients was significantly higher than that of the control group (P <0.01), and the positive rate was 75.5% The same group of serum positive rate (53.1%) (P <0.05). Conclusion: CYFRA21-1 in BALF has a high diagnostic value for lung cancer.